archived version — not current

This is a permanent, read-only archive of this profile's public content as it existed on 2026-09-27. It does not reflect the current, live profile. View the current profile.

Mazdutide

Snapshot captured 2026-09-27 — Evidence added or removed

Overview

Mazdutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic disease. Weight-management and type 2 diabetes trials have different enrolled populations, regimens, comparators, and endpoints.

Evidence quality

WPF’s atlas includes randomized-trial syntheses for overweight or obesity and comparisons with other incretin-pathway treatments. Meta-analyses and indirect network comparisons may combine heterogeneous studies; their titles do not establish comparative superiority or long-term benefit.

Safety concerns

No published source-linked citations or jurisdiction-specific regulatory records have been attached here. Trial phase, population, dose, safety follow-up, and direct versus indirect comparison need source-level appraisal.

Citations as of this version

Regulatory status as of this version

United States — FDA: not_approved
China — NMPA: approved — Mazdutide is approved by China's National Medical Products Administration for chronic weight management in adults with obesity or overweight (approved 2025-06-27), and separately for glycemic control in adults with type 2 diabetes (approved 2025-09-19).

Content hash: b45583e732ec8b0aa0fa18c5ef5b61e72377720a478c7cc34cab93c8f5b1451f

All archived versions